SANTA MONICA, Calif. — GoodRx today released a new research report that looks at insurance coverage for GIP and GLP-1 agonists like Ozempic, Wegovy, and Zepbound, including how coverage has changed from last year to 2025.
The report reveals that although there is soaring demand for popular weight-loss drugs, commercial insurance coverage for many of these medications has become significantly more restrictive in 2025. This is despite these medications’ proven efficacy and the mounting external pressure for more affordable pricing.
“Despite the fact that GLP-1 medications have proven health benefits that help millions of Americans every year, many commercial insurance plans still aren’t covering them, especially when prescribed for obesity treatment. In fact, for many people, coverage has become even more restrictive. This can cause significant strain on consumers’ wallets,” said Tori Marsh, MPH, Director of Research at GoodRx.
“At GoodRx we estimate that in the last year Americans have overspent by at least $200 million by paying full retail price for their weight-loss GIP and GLP-1 agonists. This is a huge cost burden that ultimately may stop people from accessing the medication they need and worsen health outcomes.”
Key insights from the new report include:
- More people are losing coverage: In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.
- Restrictions continue to rise for many GIP and GLP-1 medications: In 2025, over 82% of people with insurance plans that offer coverage for Wegovy, Zepbound, and Saxenda will encounter restrictions, like prior authorization or step therapy, that make access difficult.
- Use for diabetes doesn’t guarantee easy access: Even when prescribed for Type 2 diabetes, these medications often come with extra insurance hurdles - more than 75% of the time for Mounjaro and over 83% of the time for Ozempic.
You can view the full report here: Live Updates: Tracking Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound and Wegovy
